A family of nanoparticles - tiny, biodegradable molecules commonly used to deliver drugs to patients shows promise in treating Alzheimer's disease without additional medication, according to new research from a University of Alberta neuroscientist.
In a study published in Alzheimer's & Dementia, the journal of the Alzheimer's Association, Dr. Satyabrata Kar and colleagues report finding improved symptoms and reversal of the disease at the molecular and cellular level in mice with Alzheimer's following treatment with a class of nanoparticles called polylactic-co-glycolic acid, or PLGA. The nanoparticles have been approved for drug delivery in humans in the United States, Europe and Canada.
"These molecules have a long-standing safety record and are biodegradable," says Kar, a professor in the Department of Medicine.
